AbbVie walks away from Morphic deal in aftermath of safety signal in preclinical testing
AbbVie is breaking off its entire collaboration with Morphic Therapeutic around oral integrin inhibitors, just months after the pharma giant already cut away parts of the deal.
The news, disclosed in an SEC filing, marks a blow to Morphic’s small molecule approach to blocking integrins, proteins that are intended to help heal damage, but cause it when they run amok. Back in October 2018, AbbVie kicked off their pact with $100 million in cash, with the goal of developing a suite of fibrosis drugs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.